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C'ELLS of transplanted experimental
ttiniours, whein injected into genetically
compatible hosts in admixture with
Bacillus Calmette Gue'rin (BCG) organisms,
often fail to produce progressively growing
tinmouirs (Laucius et al., 1974). Host
responses are involved in this adjuvant
contact therapy, since BCG vaccines are
not directly cytotoxic for tumour cells
and systemic host immunity may follow
rejection of mixed BCG + cell inocula,
buit the precise nature of these responses
is unclear. Testswithtransplanted mouse
sarcomata (Bartlett, Zbar and Rapp, 1972;
Chung, Zbar and Rapp, 1973) demon-
strated that immunosuppression by thy-
mectomy and whole body irradiation, or
treatment with antithymocyte serum,
abrogated the local suppressive activity
of BCG. In marked contrast, Moore,
Lawrence and Nisbet (1975) have demon-
strated that immunosuppression by thy-
mectomy and irradiation does not
abrogate the contact suppressive action
of BCG( for sarcomata in the rat. In
addlition, rat tumour xenografts in con-
genitallA- athymic (nude) mice are sup-
pressed when cells are transplanted in
admixture with BCG organisms (Pimm
and Baldwin, 1975) although mice are
unable to reject fuirther challenge with
tumour cells alone.
The experiments described here were
carried out to assess the influence of host
immunosuppression on BCG contact sup-
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pression of a syngeneically tranisplanted
3-methylcholanthrene-induced rat sar-
coma, Mc7. Previous studies withl this
tumour (Baldwin and Pimm, 1.973) have
demonstrated consistent suppression- of
growth when cells are injected s.c. in
admixture with BCG, and the concomitant
generation of tumour-specific immunity
capable of suppressing growth of tuimour
cells alone injected at a distant contra-
lateral site. The effect of immuno-
suppression by whole body irradiation
on these two events has been examined.
Experiments have been carried out with
transplanted cells derived from solid
tissue and from an in vitro cultuire line,
the latter excluding the possibility of
transfer to immunosuppressed rats of
lymphoid cells present in preparationis
from solid tissue.
Tumour. Sarcoma Mc7 was induced
by the s.c. injection of 3-methylcholan-
threne and maintained by s.c. passage in
syngeneic female rats of the department's
inbred Wistar strain. This tumour is
highly immunogenic, immunized animals
rejecting up to 5 x 106 tumour cells
or grafts of whole tumour tissue, although
growth can be achieved from 2 x 105
cells in control anima,ls. Single cell
suspensions of cells from solid growths
were produced by trypsin digestion of
finely minced tumour tissue and re-
suspension in medium 1 99, their viability
as determined by trypan blue exclusionM. V. PIMM AND R. W. BALDWIN
being at least 9000. For some tests an
in vitro tissue culture line was established
and maintained in Eagle's minimal
essential medium supplemented with 10%
calf serum.
Bacillus Calmette Guerin (BCG).
Freeze-dried BCG vaccine (Percutaneous)
was supplied by Glaxo Laboratories Ltd.
(Greenford, Middlesex, England). On re-
constitution in water approximately 20%
of organisms in this vaccine are viable,
giving 3 x 108 viable organisms in 10 mg
moist weight/ml.
WT'hole body irradiation.-Rats were
exposed to 450 rad whole body y-
irradiation from a 60Co source at the rate
of 7 rad/min, 24 h before use.
Methods oftreatment. Normalorwhole
bodv irradiated rats were injected s.c.
with a mixture of defined numbers of
tumour cells (5 x 105 to 106) prepared
from solid tissue or harvested from in
vitro culture, and 200 to 500 ,ug moist
weight of BCG organisms. In some
cases, animals received a simultaneous
challenge of 106 tumour cells alone at a
contralateral subcutaneous site.
Influence of whole body irradiation on
local tumour-suppressive action of BCG.-
Table I shows the tumour-suppressive
action of BCG where injected s.c. in
admixture with cells of sarcoma Mc7
prepared from solid tissue or harvested
from in vitro culture into normal rats
and animals exposed to 450 rad y-irradia-
tion. In all tests, with both normal and
irradiated animals, admixture with BCG
prevented tumour development in almost
all rats, tumour cells alone, whether from
solid in vivo growths or in vitro culture,
growing out in the majority of normal or
irradiated animals.
Inltuence of whole body irradiation on
induction of tumour immunity by mixed
tumour cell + BCG inocula.-It has
previously been established that injection
of a mixed inoculum of sarcoma Mc7 cells
and BCG elicits tumour-specific immunity
against further challenge with cells of
the same tumour (Baldwin and Pimm,
1973). Moreover, treatment of rats with
TABLE I. Growth of Sarcoma Mc7 Cells
Injected Alone or Mixed with BCG into
Normal or Irradiated Rats
MixecI inoculum
Expt. No. cells
1 5x 105
5x 10s
5x 105
5x 105
2 106
106
'06
106
3 106
106
106
106
4t 106
106
106
106
lig BCG
200
200
200
200
500
500
500
500
Whole body
irradiation* Tuimour
(rad) takes
5/5
0/5
450 5/5
450 0/5
5/6
0/6
450 5/5
450 0/4
450
450
450
450
4/4
2/5
5/5
0/5
6/6
0/5
5/6
0/6
* 24 h before tumour injection.
t Sarcoma Mc7 cells from io vitro ctultuire.
such mixed inocula can be used for
specific active immunotherapy of a distant
challenge inoculum of up to 106 sarcoma
Mc7 cells. Table II summarizes results
of tests to examine the influence of whole
body irradiation on the ability of animals
rejecting mixed cell + BCG inocula to
control the growth of a simultaneous
challenge with tumour cells alone. In
the first test only 2/7 normal animals
rejecting mixed inocula of 106 sarcoma
Mc7 cells and 500 pg moist weight BCG
failed to reject a simultaneous challenge
inoculum of 106 cells alone on the other
side of the body. In contrast, tumours
grew out at the challenge site in all (7/7)
rats receiving whole body irradiation,
even though the animals all rejected the
mixed inoculum of tumour cells + BCG.
In two further tests, while the challenge
inoculum of cells alone grew out in only
4/10 normal animals rejecting cells +
BCG on the other side of the body, this
immunotherapeutic effect was totally
abolished in pre-irradiated animals,
challenge inocula growing out in all
(13/13) rats.
In the final test, using Mc7 cells
harvested from in vitro culture, 4/5
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TABLE II.-Growth of 106 Sarcoma Mc7
Cells* in Normal or Irradiated Rats
Rejecting Mixed Inocula of 106 Tumour
Cells + 500 #ag BCG
Whole body Takes in
irradiation
Expt. (rad) Test Control
1 2/7 6/6
450 7/7 6/6
2 3/6 6/6
450 6/6 5/5
3 - 1/4 7/7
450 7/7 7/7
4t 1/5 6/6
450 5/6 5/6
* Injected s.c. at contralateral site at the same
time as the mixed inoculum.
t Sarcoma Mc7 cells from in vitro culture.
normal animals rejecting mixed inocula
of tumour cells + BCG rejected a contra-
lateral challenge of 106 tissue-culture-
derived cells, but this therapeutic re-
sponse was abrogated in 5/6 pre-irradiated
rats.
These studies demonstrate that whole
body irradiation (450 rad) 24 h before-
hand does not abrogate the local sup-
pressive effect of BCG injected in ad-
mixture with sarcoma Mc7 cells. In
contrast, the development of tumour-
specific host immunity, normally occurring
concomitantly with rejection of mixed
inocula, was totally abrogated by whole
body irradiation. The possibility that
local contact suppression mediated by
BCG was due to lymphoid cells present in
tumour cell suspensions is excluded by
the identical results achieved with tissue-
culture-derived cells.
These findings are in contrast to those
of Bartlett et al. (1972) and Chung et al.
(1973) where full host immunocompetence,
or at least prior immunization to BCG,
was necessary for local suppression of
mouse sarcomata. However, Moore et al.
(1975), in a series of experiments with
transplanted sarcomata in the rat, have
shown that immunosuppression by sub-
lethal whole body irradiation, with or
without prior thymectomy, did not abro-
gate the local suppressive action of BCG.
In the present studies, the level of
immunosuppression produced by simple
whole body irradiation has not been
characterized, but it has been clearly
demonstrated that irradiated animals,
while rejecting mixed inocula of cells +
BCG, fail to develop the systemic tumour
immunity normally capable of controlling
a simultaneous challenge with tumour
cells alone. The present findings and
those of Moore et al. (1975) demonstrate,
therefore, that fundamentally different
host responses are involved in these two
events and that full host immunocompe-
tence is not necessary for BCG contact
therapy. This is further supported by
the previous demonstration of BCG con-
tact suppression of rat tumour xenografts
in athymic nude mice (Pimm and Baldwin,
1975).
Although the evidence presented here
suggests that augmented systemic re-
sponses to tumour-associated rejection
antigens are not essential for BCG contact
suppression, the nature of the responses
involved have yet to be elucidated. It
has been demonstrated, however, that
with rat tumours, both in syngeneic
hosts and athymic mice, the local sup-
pressive action of BCG can be abrogated
by silica treatment of the host (Hopper,
Pimm and Baldwin, 1976). Silica is
known to be selectively toxic for macro-
phages and the probability that local
BCG activation of host macrophages is
the primary tumour-suppressive event in
adjuvant contact therapy with this agent
is under investigation.
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